( o-controlled phase 3 trials for Viprine...)Presentations at 2007 European Stroke Congress Highlights New,Direction for Viprinex (ancrod),Health

o-controlled phase 3 trials for Viprinex(TM) as part of the Ancrod Stroke Program (ASP). These trials, known as ASP-I and ASP-II, will evaluate whether a brief (2 or 3 hour) infusion of ancrod begun up to six hours after onset of stroke can reduce stroke related disability. ASP-I and II are currently enrolling and each trial is planned to enrol 650 patients. Patient accrual began in November 2005. The trials are being conducted in the U.S., Europe, South Africa, Australia, and New Zealand. Additional countries will be entering the program. The company expects that the trials will be conducted at up to 130 sites worldwide and that approximately 70% of the ASP-I sites and approximately 50% of the ASP-II sites will be located within the U.S. Patients who qualify for enrolment into the clinical trials will receive a two or three-hour intravenous infusion of ancrod or placebo within six hours of stroke onset. If treated within three hours of stroke onset, subjects must have been determined unsuitable for treatment with tPA.

"We have data showing that fibrinogen plays a significant role in influencing stroke outcome. Ancrod directly targets fibrinogen and has the potential to treat strokes by rapidly lowering fibrinogen levels," said David E. Levy, MD, Vice President of Clinical Development for NTI. "We are aggressively recruiting patients worldwide for the ASP-I and ASP-II studies. We hope by garnering a large patient base for the study we can generate the robust data needed to confirm our new dosing strategy and six hour treatment window for acute ischemic stroke."

About Viprinex(TM) (ancrod)

Ancrod, a novel reperfusion agent being investigated for acute ischemic stroke (AIS), is a defibrinogenating enzyme derived from the venom of the Malayan pit viper, a potent, natural anticoagulant. 'Reperfusion' means that it helps restore blood flow. Ancrod does this by acting directly on fibrinogen, a protein involved in blood clotting. Ancrod cleaves fibrino
'"/>

Page: 1 2 3 4
Related medicine technology :

1. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
2. Nuvelo Announces Presentations on rNAPc2 and NU172 at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
4. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Mechanism of Action and Clinical Activity of Sulonex(TM) (sulodexide oral gelcap) at the Upcoming American Diabetes Association 67th Scientific Sessions in Chicago, Illinois
5. Inspire Announces Presentations at Two European Scientific Conferences
6. IDM Pharma Announces UVIDEM(R) and EP-2101 Data Presentations at 2007 ASCO Annual Meeting
7. MedImmune Highlights Advances in Inflammatory Disease Pipeline With Series of Data Presentations
8. Pharmacyclics Announces Presentations and Published Abstracts on Xcytrin at The 2007 American Society of Clinical Oncology Annual Meeting
9. Schering-Plough Announces Hepatitis C Data Presentations at Digestive Disease Week (DDW) 2007 Annual Meeting
10. Lux Biosciences Investigational Therapy for Uveitis, LX211, is Subject of Two Presentations at Key Ophthalmology Meeting, ARVO 2007
11. Inspire Announces Presentations at 2007 Association for Research in Vision and Ophthalmology Annual Meeting